Rigel Pharmaceuticals (RIGL) Non-Current Deffered Revenue (2010 - 2020)

Rigel Pharmaceuticals' Non-Current Deffered Revenue history runs 11 years deep, the most recent figure standing at $146000.0 for Q3 2020.

• On a quarterly basis, Non-Current Deffered Revenue fell 99.42% year-over-year to $146000.0 in Q3 2020; TTM through Sep 2020 was $146000.0, a 99.42% decrease from a year earlier, with the FY2019 full-year figure at $1.4 million, changed 0.28% from the prior year.
• Non-Current Deffered Revenue eased to $146000.0 in Q3 2020 per RIGL's latest filing, from $1.6 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $26.4 million in Q2 2019 and bottomed at $90000.0 in Q4 2017.
• The 5-year median for Non-Current Deffered Revenue is $1.4 million (2018), against an average of $6.3 million.
• Across the five-year window, Non-Current Deffered Revenue surged 14720.79% in 2019 and slumped 99.42% in 2020, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $279000.0 in 2016, then slumped by 67.74% to $90000.0 in 2017, then surged by 1464.44% to $1.4 million in 2018, then dropped by 0.28% to $1.4 million in 2019, then slumped by 89.6% to $146000.0 in 2020.
• Per Business Quant, the three latest RIGL Non-Current Deffered Revenue figures stand at $146000.0 (Q3 2020), $1.6 million (Q1 2020), and $1.4 million (Q4 2019).